awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37630473-8C820251-391C-4556-A297-186C99BEF0AB
Q37630473-8C820251-391C-4556-A297-186C99BEF0AB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37630473-8C820251-391C-4556-A297-186C99BEF0AB
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
P2860
Q37630473-8C820251-391C-4556-A297-186C99BEF0AB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37630473-8C820251-391C-4556-A297-186C99BEF0AB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
87714611a8a9d60c47686f95cfc70a792bd244f8
P2860
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer